Spark Therapeutics Inc

Wall Street analysts expect a potential upside of 19.21% for bluebird bio (BLUE) based on the company’s closing price on March 27.

Wall Street analysts have projected Spark Therapeutics’ revenues to be $105.64 million, $169.22 million, and $263.76 million for fiscal 2019, fiscal 2020, and fiscal 2021, respectively.

On February 25, Roche Holdings (RHHBY) issued a press release announcing that it has entered a definitive agreement to acquire Spark Therapeutics (ONCE).

In the first nine months of 2018, Sangamo Therapeutics (SGMO) reported net income of -$49.7 million compared to -$41.5 million in the same period the prior year.

On November 15, uniQure (QURE) stock closed at $30.93, which reflected a ~35.66% rise from its previous day’s close of $22.80.

In November, among the ten analysts covering Editas Medicine (EDIT), six analysts recommended a “buy,” while four recommended a “hold.”

Spark Therapeutics’ (ONCE) operating expenses decreased from $78.48 million in Q2 2017 to $59.78 million in Q2 2018.

Spark Therapeutics generated revenues of $25.18 million in the second quarter of 2018 compared to $1.48 million in Q2 2017.

Stocks focused on gene therapy have garnered strong investor interest in 2018. In this series, we’ll analyze four of those companies.

On September 10, Intellia Therapeutics stock closed at $26.98, a ~0.95% fall from the previous day’s close of $27.24.

Editas Medicine (EDIT) is a research-stage genome editing company. Five of the total nine analysts covering the company in August have given the stock a “buy” rating.

Yesterday, Achaogen (AKAO) announced that the FDA had approved its antibacterial agent, Zemdri (plazomicin), for adults suffering from complicated urinary tract infections (or cUTI) who don’t have significant treatment options.

Axovant Sciences (AXON) stock jumped ~160.0% to the closing price of $4.55 on June 6.

In May, Jazz Pharmaceuticals (JAZZ) submitted a supplemental new drug application to the FDA for the label expansion of Xyrem.

Of the 19 analysts covering Sarepta Therapeutics in April 2018, six analysts gave the stock a “strong buy” rating.

Of eight analysts tracking Tetraphase Pharmaceuticals, one analyst rated it as a “strong buy,” and six analysts gave it a “buy” rating.

Spark Therapeutics (ONCE) used $154.5 million in operating activities in 2017 compared to $80.4 million in 2016.

Spark Therapeutics’ Luxturna was approved by the FDA in December 2017. It’s the first gene therapy approved for the treatment of a genetic disease.

Of the 20 analysts covering Spark Therapeutics in April 2018, four have given the stock “strong buy” recommendations.

Voyager Therapeutics is a clinical-stage gene therapy company with a focus on developing treatments for severe neurological diseases.

On March 29, 2018, Spark Therapeutics was trading at $66.59, which represented a ~62% increase from its 52-week low of $41.06.

The recent developments for Pfizer (PFE) include various product developments, pipeline developments, and commercial developments.